Can a reformulated gel plus light therapy better tackle precancerous skin spots?

NCT ID NCT07729579

First seen Jul 27, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This trial is testing a reformulated version of a topical drug called Levulan Kerastick, which is applied to actinic keratosis (AK) lesions on the face or forearms. After the drug sits on the skin for a few hours, it is activated by blue light in a process called photodynamic therapy (PDT). The study aims to measure how much of the drug enters the bloodstream and to check for any side effects in people with multiple AK spots.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a reformulated topical solution of aminolevulinic acid hydrochloride (ALA HCl) 20%, applied as Levulan Kerastick followed by blue light photodynamic therapy
What this could lead to
If successful, this could lead to a more effective and convenient treatment for actinic keratosis, a common precancerous skin condition.
What could go wrong
This is an early phase 1 study with only 48 participants, so it is primarily checking safety and how the drug moves through the body, not yet whether it works better than existing treatments. Side effects from the drug or light therapy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACTINIC KERATOSIS (AK) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • J&S Studies

    RECRUITING

    College Station, Texas, 77845, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.